Ontario, Canada-based Nordion Inc. disclosed Wednesday in a Form 6-K (Report of Foreign Private Issuer) filed with the SEC that it’s investigating a foreign supplier and other third parties for potential FCPA and Canadian law compliance issues.
Nordia (NYSE: NDZ) makes cancer-treatment products.
In it’s disclosure it said:
On August 8, 2012, subsequent to the third quarter of 2012, Nordion voluntarily disclosed that it was conducting an internal inquiry and investigation of a foreign supplier and other third parties focusing on compliance with the Canadian Corruption of Foreign Public Officials Act and the U.S. Foreign Corrupt Practices Act. The Company continues investigating this matter and is cooperating with regulatory and enforcement authorities. Based on the investigation conducted to date, Nordion currently does not expect an impact on revenue in 2012 or 2013 or a material impact on supplies necessary for current business operations.
Research by ethiXbase.